Prof. Efrat Dotan is the executive medical director for Penn Medicine Ann B. Barshinger Cancer Institute in Lancaster, Pennsylvania. She graduated from the Technion Institute of Technology Medical School in Israel and moved to the US to pursue her specialized training. She completed her residency at Lenox Hill Hospital in New York, and her hematology/oncology fellowship at Fox Chase Cancer Center. Prof. Dotan specializes in the management of patients with gastrointestinal malignancies, specifically pancreatic cancer. Her research interest is in development of new treatment options for patients with gastrointestinal cancers. She is the PI for multiple clinical trials in this arena. Prof. Dotan is a member of the Gastrointestinal Malignancies Committee of the Eastern Cooperative Oncology Group (ECOG), serves as the PI for multiple studies and is co-chair of the NCI pancreatic task force. Dr Dotan’s other interest is in the management of older patients with cancer, developing treatment strategies and tools to improve the care of this patient population. She has led multiple research projects evaluating the care of older patients with gastrointestinal malignancies. She is a senior member of the Cancer and Aging Research Group, the chair of the Older Adult Oncology Guidelines for NCCN and the chair of the geriatric oncology working group for ECOG.

Prof. Efrat Dotan has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, Dragonfly, Gilead, Incyte, Ipsen, Kinnate, Leap therapeutics, Lutris, MedImmune, Merck, MERUS, Olympus, Pfizer, Relay, TME biopharmaceuticals, Zymeworks